Breast Cancer

Drugs commonly used to treat osteoporosis may benefit patients with diseases like breast cancer.

Cost of medication causes financial burden for nearly two-thirds of patients.

Dispensing generic hormonal therapies instead of their brand-name counterparts increases breast cancer patients' life-saving medication adherence by 50%.

Nanotechnology and shortwave infrared light reveals small tumors and cardiovascular lesions deep inside body.

Researchers found significant improvements in overall survival and in disease-free survival in patients who received trastuzumab in addition to chemotherapy.

Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.

An estimated 6.9 million US adults aged 35 years and older had a combined 10.9 million self-reported smoking-attributable medical conditions in 2009.

Palbociclib provides first-line systemic treatment for women with advanced or metastatic breast cancer.

The FDA today granted priority review status to a breakthrough breast cancer drug developed by Pfizer Inc.

Brand name, patent-protected medications drive increasing costs.

Researchers in Finland are learning more about how hormones influence the risk of developing breast cancer, which may lead to a hormone-based treatment to reduce the risk of developing cancer later in life.

Patients who smoke both traditional and e-cigarettes less likely to quit than those who only smoke traditional cigarettes.

A combination of Lactobacillus plantarum and a modified inulin derivative reduced expression of T-cells in mammary cancers induced in rats.

A recent metaanalysis suggests that prediabetes increases the risk of developing certain cancers, particularly in tissues located near the gastrointestinal tract.

Researchers in Japan are beginning to construct patient-centered counseling techniques for breast cancer by evaluating patient preference.

One major challenge in breast cancer is determining which treatment will be most effective for an individual patient's tumor. With a genetic panel, the TAXSig system may help change that.

A prognostic disease marker that often occurs in patients with triple-negative breast cancer may lead to development of a medication to close a therapeutic gap in targeted cancer treatment.

Regina, a licensed pharmacist for more than 20 years, developed breast cancer at 48 years of age.

A recent meta-analysis published in the journal Plos One indicates a potential link between breast cancer and use of a common blood pressure medication, but a closer look tells a different story.

Medicaid beneficiaries are more likely to be screened for 3 types of cancer in states where physicians receive higher payments for office visits, a study suggests.

Specialty therapies for rheumatoid arthritis, multiple sclerosis, and breast cancer tended to have positive functional and clinical outcomes for patients.

A phase 2 trial reported 100% 3-year overall survival rates with frontline therapy consisting of lenalidomide, bortezomib, and dexamethasone in younger patients with multiple myeloma.

More than 90% of women in the program received timely follow-up care.

In a study that has the potential to change public health recommendations for breast cancer screening, researchers have validated the value of mammography in older women.

More than 90% of women in the program received timely follow-up care.

Launch of premium-priced agents powering growth forecast.

Targeted therapies used in conjunction with chemotherapy may offer benefits to patients with triple-negative breast cancer.